Insulet Corporation Overview
Pro stress-test →Insulet Corporation is the global leader in tubeless insulin pump technology with its Omnipod brand of products. Once pigeonholed as a niche player in the Type 1 diabetes market, the company has transformed into a high-growth med-tech powerhouse with successful integration of its automated insulin delivery (AID) system and massive expansion into the Type 2 diabetes population. Insulet is focused on driving growth within its $30 billion-plus total addressable market.
Strategic Profile
Pro stress-test →The Omnipod 5 Automated Insulin Delivery System integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections and can be controlled by a compatible personal smartphone in the U.S. By early 2026, the company has successfully debunked the GLP-1 death sentence narrative and proved that its tubeless, pharmacy-distributed model is the most scalable way to manage insulin-dependent diabetes. Adjusted Diluted Earnings Per Share are anticipated to grow at a CAGR of 25%+.
Competitive Landscape
Pro stress-test →Insulet disrupted the paradigm with the Omnipod as the world's first tubeless, wearable insulin Pod. The company competes in the insulin delivery market against traditional tubed pump systems and multiple daily injection therapy. Key competitors include established medical device companies offering traditional tubed pump systems and newer players in automated insulin delivery.
Industry Context
Insulet Corporation operates in Medical Devices - Insulin Delivery Systems / Automated Insulin Delivery (AID).
Key facts
Founded: 2000 · Headquarters: Acton, Massachusetts · Revenue: $2.07B (2024)